SEC Form 4 · accession 0001144204-15-069180
BRAINSTORM CELL THERAPEUTICS INC. · BCLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yoram Bibring
Officer — Chief Financial Officer
Period of report
Dec 1, 2015
Accepted (ET)
Dec 3, 2015 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001137883
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.17 | Dec 1, 2015 | D | 82,500 | A | Jul 30, 2016 | Jul 30, 2025 | Common Stock | 82,500 | 82,500 | D |
Explanation of responses
- F1Effective December 1, 2015, the option granted by the Issuer to the Reporting Person on July 30, 2015 was amended such that 82,500 of the 165,000 shares are cancelled. The 82,500 remaining shares continue to vest and become exercisable in accordance with their terms: 20,625 shares vest and become exercisable on July 30, 2016 and 2.08333% of the 82,500 shares vest and become exercisable on each monthly anniversary date starting on August 30, 2016 through the fourth anniversary of the grant, so that the 82,500 shares will become fully vested and exercisable on July 30, 2019. In connection with the cancellation the Reporting Person became a half-time employee of the Issuer, but received no cash consideration for the cancellation.